IND clearance for OXU-001
We are thrilled to announce the IND clearance for suprachoroidal OXU-001,
Menu
Menu
Targeted, safe, long-lasting retinal treatments
Oxular is transforming the treatment of retinal disorders to improve patients’ vision so they can live better lives.
Targeted, safe, long-lasting retinal treatments
Oxular is transforming the treatment of retinal disorders to improve patients’ vision so they can live better lives.
Latest News
Oxular at Dry AMD Conference
Oxular’s CMO, Friedrich Asmus, MD, spoke at the Dry AMD Therapeutic Development
New Oxular CBO – James Jogerst
OXFORD, UK – November 7, 2022 – Oxular Limited, a clinical-stage
Latest News
Oxular's innovative technology...
Targeted, routine suprachoroidal delivery
Long-lasting treatments
...transforms the treatment paradigm…
Significantly fewer treatments
Sustained efficacy
Better safety
Better delivery
Significantly fewer treatments
Better delivery
Sustained efficacy
Better safety
...to offer novel approaches for retinal specialists and meaningful benefits for patients.
- Best-in-class or first-in-class treatments
- Sustained treatment benefits, leading to fewer injections and better patient outcomes and adherence
- Better safety through targeted drug delivery with enriched choroidal-retinal exposure
- Reduced treatment burden and related costs for healthcare systems
Putting innovation into action
| Targeted, routine, suprachoroidal delivery | Long-lasting treatments | |||
Oxulumis® |
Oxuspheres™ |
|||
|
|
|||
| Pipeline programs | ||||
High prevalence retinal disorders |
||||
| Diabetic macular edema (DME), retinal vein occlusion (RVO), uveitis
Diabetic retinopathy |
||||
Future opportunities |
||||
Indications |
Modalities |
|||
| Geographic atrophy / intermediate AMD
Neovascular AMD Uveal melanoma Neuroprotection Front-of-eye |
Small molecules
AAV gene therapies Peptides/proteins Antibodies siRNA |
|||
Building a leading retinal therapeutics franchise
Oxular is committed to transforming the treatment paradigm for sight-threatening retinal disorders by providing safe, durable therapeutics that are precisely delivered to specific ocular tissues to control disease activity.
We have…
Exceptional R&D capability and best-in-class technology
Near-term, high-value, differentiated product pipeline
Strong leadership with a proven history
Value-added relationships with industry partners
Strong syndicate of top-tier healthcare investors
Our Site
Menu
General Contact
+44 (0)1865 636200
Magdalen Centre
1 Robert Robinson Avenue
Oxford, OX4 4GA, UK
Media Contact
Ben Atwell / Alex Davis
FTI Consulting
London
Limited company registered in England and Wales (Registration No. 09331313)
VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting
Follow us on
Limited company registered in England and Wales (Registration No. 09331313) VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting